Scott Smith - Ascendis Pharma Sr CFO
| A1SN34 Stock | BRL 53.35 1.65 3.00% |
Insider
Scott Smith is Sr CFO of Ascendis Pharma AS
| Age | 49 |
| Phone | 45 70 22 22 44 |
| Web | https://ascendispharma.com |
Scott Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Smith against Ascendis Pharma stock is an integral part of due diligence when investing in Ascendis Pharma. Scott Smith insider activity provides valuable insight into whether Ascendis Pharma is net buyers or sellers over its current business cycle. Note, Ascendis Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ascendis Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Smith over three months ago Disposition of 1791 shares by Scott Smith of Bioatla at 3.0 subject to Rule 16b-3 | ||
Scott Smith over six months ago Disposition of 2181 shares by Scott Smith of BioatlaInc at 2.26 subject to Rule 16b-3 | ||
Scott Smith over a year ago Payment of 1791 shares by Scott Smith of BioatlaInc subject to Rule 16b-3 | ||
Scott Smith over a year ago Payment of 1791 shares by Scott Smith of BioatlaInc subject to Rule 16b-3 |
Ascendis Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2658) % which means that it has lost $0.2658 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6669) %, meaning that it generated substantial loss on money invested by shareholders. Ascendis Pharma's management efficiency ratios could be used to measure how well Ascendis Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Brian Michaud | Automatic Data Processing | 51 | |
| Sandra Wijnberg | Automatic Data Processing | 63 | |
| Christian Greyenbuhl | Automatic Data Processing | N/A | |
| Peter Bisson | Automatic Data Processing | 62 | |
| Brent Hyder | salesforce inc | 58 | |
| Jessica Graziano | United States Steel | 50 | |
| Nazzic Keene | Automatic Data Processing | 58 | |
| Maria Black | Automatic Data Processing | 49 | |
| Kareem Chin | Warner Music Group | N/A | |
| Brock Albinson | Automatic Data Processing | 48 | |
| Laura Brown | Automatic Data Processing | 47 | |
| Steve Bugajski | United States Steel | N/A | |
| Manpreet Grewal | United States Steel | 44 | |
| Max Lousada | Warner Music Group | 50 | |
| Vipul Nagrath | Automatic Data Processing | N/A | |
| Deborah Dyson | Automatic Data Processing | 53 | |
| James Steven | Warner Music Group | 46 | |
| Kimberly Fast | United States Steel | 45 | |
| Sreeni kutam | Automatic Data Processing | 49 | |
| Michael Bonarti | Automatic Data Processing | 58 | |
| Trent Esq | Warner Music Group | N/A | |
Management Performance
| Return On Equity | -0.67 | |||
| Return On Asset | -0.27 |
Ascendis Pharma AS Leadership Team
Elected by the shareholders, the Ascendis Pharma's board of directors comprises two types of representatives: Ascendis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascendis. The board's role is to monitor Ascendis Pharma's management team and ensure that shareholders' interests are well served. Ascendis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascendis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Flemming Jensen, VP Quality | ||
| Scott Smith, Sr CFO | ||
| Michael LLM, Chief VP | ||
| Jan Mikkelsen, CEO and President | ||
| Birgitte MD, Sr Affairs | ||
| Timothy Lee, Director Relations | ||
| Lotte Sonderbjerg, Sr Officer | ||
| Peter Rasmussen, VP Officer | ||
| Kennett Sprogoe, VP Research | ||
| Jens Okkels, VP Devel |
Ascendis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ascendis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (15.89) % | |||
| Current Valuation | 34.82 B | |||
| Shares Outstanding | 57.03 M | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 1,080 X | |||
| Revenue | 7.78 M | |||
| Gross Profit | 4.25 M | |||
| EBITDA | (364.64 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Ascendis Stock
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.